MOIO at #ESMO26: 12-week vs standard ICI in patients responding at 6 months. Stopped early, futility bar not crossed.

📉 mITT PFS HR 1.35, median 21.9 vs 25.0 months
⚠️ OS HR 2.04 (1.08 to 3.85), 31 vs 16 deaths (stopped by DSMC)
🧪 UC PFS HR 2.91 (1.27 to 6.67), RCC 0.68 (0.32 to 1.44).

Hypothesis-generating. No safety advantage. Results can't support 12-week dosing in responders. Congrats on this huge effort, inferiority trials hard to run, pragmatic trial to better understand schedule of IO therapy.
#ESMO26 #GUonc #Immunotherapy